A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
← catalyst calendarNCT06544655 · readout in 420 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
213estimated
Sites
9
Countries
Australia, Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-10 | actual | When the study began enrolling |
| Primary completion | 2027-10-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-14 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: BMS-986484
- Biological: Nivolumab — also filed as Opdivo
- Drug: Oxaliplatin
- Drug: Capecitabine
- Drug: Fluorouracil
- Drug: Calcium folinate
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events (AEs)
measured Up to approximately 2 years
Incidence of serious adverse events (SAEs)
measured Up to approximately 2 years
Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria
measured Up to approximately 28 days
Incidence of AEs leading to discontinuation
measured Up to approximately 2 years
Incidence of AEs leading to death
measured Up to approximately 2 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed